Literature DB >> 15969874

Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale.

Joseph C Cappelleri1, Andrew G Bushmakin, Christine L Baker, Elizabeth Merikle, Abayomi O Olufade, David G Gilbert.   

Abstract

OBJECTIVES: The version of the Minnesota Nicotine Withdrawal Scale (MNWS) under consideration consists of nine items. No psychometric analyses of this version have been published. The objectives of this investigation were to perform a factor analysis and to further assess the psychometric properties of the MNWS. RESEARCH DESIGN AND METHODS: Data came from three Phase II clinical trials on varenicline, developed for smoking cessation, in a sample of smokers. Exploratory factor analysis was used to examine the structure of the MNWS in the first completed study (n = 626) over various time periods. The postulated factor structure was then tested in a set of confirmatory analyses conducted on two subsequent studies (n = 627, n = 312). The proposed structure was further evaluated through construct validity and reliability analyses. MAIN OUTCOME MEASURES: The nine items of the MNWS included the following: urge to smoke (craving); depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; and difficulty staying asleep. Each item was rated by a subject on an ordinal scale from 0 (not at all) to 4 (extreme).
RESULTS: Scree plots and rotated factor patterns from the exploratory factor analyses revealed two multi-item domains--Negative Affect with four items and Insomnia with two items--and three individual items (Craving, Restlessness, Increased Appetite). Confirmatory factor analyses supported the structure with fit indexes exceeding 0.90. The multidimensional framework of the MNWS correlated as expected with health status, depicted an expected course of withdrawal symptoms over time, predicted the sensitivity of withdrawal symptoms on subsequent cessation, and produced internal reliability estimates above 0.70.
CONCLUSIONS: Evidence is obtained to support the validity and reliability of the multidimensional structure of the nine-item MNWS. The data suggest that the MNWS has individual constructs on Negative Affect (depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating), Insomnia (difficulty going to sleep; difficulty staying asleep), Craving, Restlessness, and Increased Appetite. As such, analyzing each construct separately would strengthen the analysis of the popular MNWS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969874     DOI: 10.1185/030079905X43712

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  25 in total

1.  Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.

Authors:  Qu Cui; Linda Robinson; Dawn Elston; Fiona Smaill; Jeffrey Cohen; Corinna Quan; Nancy McFarland; Lehana Thabane; Andrew McIvor; Johannes Zeidler; Marek Smieja
Journal:  AIDS Patient Care STDS       Date:  2011-10-18       Impact factor: 5.078

2.  Validity of the 12-item French version of the Tobacco Craving Questionnaire in treatment-seeking smokers.

Authors:  Ivan Berlin; Edward G Singleton; Stephen J Heishman
Journal:  Nicotine Tob Res       Date:  2010-03-24       Impact factor: 4.244

3.  Mecamylamine treatment for alcohol dependence: a randomized controlled trial.

Authors:  Ismene L Petrakis; Elizabeth Ralevski; Ralitza Gueorguieva; Stephanie S O'Malley; Albert Arias; Kevin A Sevarino; Jane S Jane; Erin O'Brien; John H Krystal
Journal:  Addiction       Date:  2017-10-12       Impact factor: 6.526

Review 4.  Withdrawal: Expanding a Key Addiction Construct.

Authors:  Megan E Piper
Journal:  Nicotine Tob Res       Date:  2015-03-05       Impact factor: 4.244

5.  Withdrawal Symptom, Treatment Mechanism, and/or Side Effect? Developing an Explicit Measurement Model for Smoking Cessation Research.

Authors:  Sarah S Tonkin; Trevor F Williams; Leonard J Simms; Stephen T Tiffany; Martin C Mahoney; Robert A Schnoll; Paul M Cinciripini; Larry W Hawk
Journal:  Nicotine Tob Res       Date:  2020-04-17       Impact factor: 4.244

6.  Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.

Authors:  Patanjali Ravva; Marc R Gastonguay; Hélène M Faessel; Theodore C Lee; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2014-08-21       Impact factor: 4.244

7.  A telephone-based intervention to promote physical activity during smoking cessation: a randomized controlled proof-of-concept study.

Authors:  Uma S Nair; Freda Patterson; Daniel Rodriguez; Bradley N Collins
Journal:  Transl Behav Med       Date:  2017-06       Impact factor: 3.046

8.  A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Miguel Alvarez-Estrada; Arthur L Brody
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

9.  Tobacco withdrawal components and their relations with cessation success.

Authors:  Megan E Piper; Tanya R Schlam; Jessica W Cook; Megan A Sheffer; Stevens S Smith; Wei-Yin Loh; Daniel M Bolt; Su-Young Kim; Jesse T Kaye; Kathryn R Hefner; Timothy B Baker
Journal:  Psychopharmacology (Berl)       Date:  2011-03-18       Impact factor: 4.530

10.  Association of tobacco dependence and quit attempt duration with Rasch-modeled withdrawal sensitivity using retrospective measures.

Authors:  Harold S Javitz; Janet Brigham; Christina N Lessov-Schlaggar; Ruth E Krasnow; Gary E Swan
Journal:  Addiction       Date:  2009-06       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.